Audio – Stemcell funding could spark U.S. breakthrough in medicine

November 7, 2006

Stemcell research funding proved to be a hot-button issue in the Congressional races leading up to election day this week — but it’s clear where Big Pharma stands on the new technology. Novartis’ head of corporate research told the Reuters Summit in a phone interview that he sees major breakthroughs in the U.S. if federal funding were ever to get approval.

No comments so far

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see